We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lower Cut-Off Point of Blood Glucose May Define Prediabetes

By LabMedica International staff writers
Posted on 15 Dec 2016
Print article
Doctors define prediabetes as impaired fasting glucose with a higher than normal blood sugar levels after a period of fasting, impaired glucose tolerance with a higher than normal blood sugar levels after eating, or raised glycosylated hemoglobin levels.

Results of studies on the association between prediabetes and risk of cardiovascular disease and all-cause mortality are also inconsistent. Furthermore, whether raised glycosylated hemoglobin levels for defining prediabetes is useful for predicting future cardiovascular disease is unclear.

Scientists affiliated with the Affiliated Hospital at Shunde, (Southern Medical University, Foshan, China) analyzed the results of 53 studies involving over 1.6 million individuals to shed more light on associations between different definitions of prediabetes and the risk of cardiovascular disease, coronary heart disease, stroke, and all-cause mortality.

Prediabetes was defined as impaired fasting glucose according to the criteria of the American Diabetes Association (ADA, Arlington County, VA, USA; IFG-ADA; fasting glucose 5.6-6.9 mmol/L), the World Health Organization expert group (WHO, Geneva, Switzerland; IFG-WHO; fasting glucose 6.1-6.9 mmol/L), impaired glucose tolerance (two hour plasma glucose concentration 7.8-11.0 mmol/L during an oral glucose tolerance test), or raised hemoglobin A1c (HbA1c) of 39-47 mmol/mol (5.7-6.4%) according to ADA criteria or 42-47 mmol/mol (6.0-6.4%).

The scientists found that prediabetes, defined as impaired fasting glucose or impaired glucose tolerance, was associated with an increased risk of cardiovascular disease and all-cause mortality. The risk increased in people with a fasting glucose concentration as low as 5.6 mmol/L (100.8 mg/dL), which was the lower cut-off point according to ADA criteria. Raised HbA1c levels to 39-47 mmol/mol or 42-47 mmol/mol were both associated with an increased risk of composite cardiovascular disease and coronary heart disease but not with an increased risk of stroke and all-cause mortality.

The authors concluded that prediabetes, defined as impaired glucose tolerance, impaired fasting glucose, or raised HbA1c, was associated with an increased risk of cardiovascular disease. The health risk might be increased in people with a fasting glucose concentration as low as 5.6 mmol/L or HbA1c of 39 mmol/mol. The study was published on November 23, 2016, in the journal BMJ.

Related Links:
Southern Medical University
American Diabetes Association
World Health Organization
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
Pipet Controller
Stripettor Pro

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.